Evidence map›Paper›PMID 42432433›Full record

ArticleChemMedChem2026

Pyridyl-Imidazopyridine Derivatives Displaying Submicromolar Activity Against Trypanosoma cruzi.

Ana Carolina Rocha Barreto, Kelly Lopes Figueira, Raquel Azevedo, Ketlym da Conceição, Ludmila de Ferreira de Almeida Fiuza, Luan Dos Santos Vianna, Thiago Apolinário de Moraes, Wagner Alves de Souza Júdice, Maria de Nazaré Correia Soeiro, Jones Limberger

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Ana Carolina Rocha BarretoDepartment of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
Kelly Lopes FigueiraDepartment of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.
Raquel AzevedoCell Biology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.
Ketlym da ConceiçãoCell Biology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.
Ludmila de Ferreira de Almeida FiuzaCell Biology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.
Luan Dos Santos ViannaInterdisciplinary Center for Biochemical Research, University of Mogi das Cruzes, Mogi das Cruzes, Brazil.
Thiago Apolinário de MoraesInterdisciplinary Center for Biochemical Research, University of Mogi das Cruzes, Mogi das Cruzes, Brazil.
Wagner Alves de Souza JúdiceInterdisciplinary Center for Biochemical Research, University of Mogi das Cruzes, Mogi das Cruzes, Brazil.
Maria de Nazaré Correia SoeiroCell Biology Laboratory, Oswaldo Cruz Institute, Oswaldo Cruz Foundation, Rio de Janeiro, Rio de Janeiro, Brazil.
Jones LimbergerDepartment of Chemistry, Pontifical Catholic University of Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil.

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior 001Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro SEI-260003/001526/2022Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro SEI-260003/003400/2022Fundação de Amparo à Pesquisa do Estado de São Paulo 2014/02205-1Fundação de Amparo à Pesquisa do Estado de São Paulo 2016/25112-4Fundação de Amparo à Pesquisa do Estado de São Paulo 2021/01503-2
6 · The paper itself

Abstract

Chagas disease, caused by the protozoan Trypanosoma cruzi (T. cruzi), remains a major public health challenge due to the limited efficacy and high toxicity of current treatments. In this study, we describe the design and synthesis of 10 imidazo[1,2-a]pyridine derivatives as potential antitrypanosomal agents. All compounds were evaluated in vitro against intracellular forms of T. cruzi, and the most active were further assessed for cytotoxicity and cruzain inhibition. Molecular docking studies were also conducted to investigate their binding modes in the enzyme active site. Some pyridyl-substituted derivatives showed high potency, with submicromolar EC

Indexed as

ImidazolesPyridinesTrypanocidal AgentsTrypanosoma cruziAnimalsCysteine EndopeptidasesDose-Response Relationship, DrugHumansMolecular Docking SimulationMolecular StructureParasitic Sensitivity TestsProtozoan ProteinsStructure-Activity Relationshipcruzain, Trypanosoma cruziCysteine EndopeptidasesImidazolesimidazopyridineProtozoan ProteinsPyridinesTrypanocidal Agentsantitrypanosomal activityChagas diseasecruzainimidazopyridinesmolecular docking

Identifiers

PMID42432433
PMCPMC13354723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.